SGLT2 Inhibitors Market to Grow with a CAGR of 5.90% through 2030

Surge in research and development activities is expected to drive the Global SGLT2 Inhibitors Market growth in the forecast period, 2026-2030.

According to TechSci Research report, “SGLT2 Inhibitors Market - Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2030F”, the Global SGLT2 Inhibitors Market stood at USD 15.37 Billion in 2024 and is anticipated to grow with a CAGR of 5.90% through 2030. Initiatives taken by government based on SGLT2 inhibitors has led to favorable market conditions for the Global SGLT2 Inhibitors Market. Several factors contribute to the growth of various SGLT2 inhibitors products.

In several developed markets, government health agencies have incorporated SGLT2 inhibitors into national diabetes treatment guidelines and formularies. For example, the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved SGLT2 inhibitors not only for glycemic control in type 2 diabetes but also for heart failure and chronic kidney disease, based on growing clinical evidence. These expanded indications have prompted public health systems to reconsider reimbursement policies to support broader patient access.

Ongoing R&D efforts are focused on combination therapies, drug reformulations, and personalized medicine approaches to further improve treatment outcomes. Additionally, research is exploring the use of SGLT2 inhibitors in type 1 diabetes, non-diabetic kidney disease, and obesity management indications that could further drive market expansion upon regulatory approval.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global SGLT2 Inhibitors Market”

The Global SGLT2 Inhibitors Market is segmented into drug, indication, regional distribution, and company.

Based on Drug, Farmiga have emerged as the dominating segment in the Global SGLT2 Inhibitors Market in 2024. This is due to its broad clinical utility, extensive regulatory approvals, and strong commercial execution. Originally approved for type 2 diabetes, Farxiga has since secured additional indications for heart failure (with and without reduced ejection fraction) and chronic kidney disease, significantly expanding its patient base. This multi-indication versatility has positioned Farxiga as a go-to therapy across multiple specialties, including endocrinology, cardiology, and nephrology.

Based on Region, Asia Pacific have emerged as the fastest growing region in the Global SGLT2 Inhibitors Market in 2024. Improved healthcare infrastructure, rising healthcare expenditure, and broader access to insurance coverage across countries such as China, India, Japan, and South Korea have facilitated greater adoption of advanced diabetes treatments. Governments and health authorities in the region are increasingly focused on addressing non-communicable diseases, supporting early diagnosis and treatment strategies that include SGLT2 inhibitors.

Major companies operating in Global SGLT2 Inhibitors Market are:

• Boehringer Ingelheim International GmbH
• AstraZeneca
• Merck & Co., Inc.
• Janssen Pharmaceuticals, Inc.
• TheracosBio, LLC
• Lexicon Pharmaceuticals, Inc.
• Eli Lilly and Company
• Bristol-Myers Squibb Company
• Glenmark Pharmaceuticals Ltd.

Download Free Sample Report

Customers can also request for 10% free customization on this report

“One of the most promising applications is the use of nanocarriers including nanoparticles, nanoemulsions, and liposomes to improve the pharmacokinetic profiles of SGLT2 inhibitors. These nanoscale delivery systems can enhance drug solubility and absorption, allowing for more consistent therapeutic levels with potentially lower doses. This not only improves efficacy but also reduces the likelihood of side effects, such as genitourinary infections, commonly associated with these therapies”, said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm.

“SGLT2 Inhibitors Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug (Jardiance, Farmiga, Inpefa, Invokana, Others), By Indication (Type 2 Diabetes, Cardiovascular, Others), By Region and Competition, 2020-2030F”, has evaluated the future growth potential of Global SGLT2 Inhibitors Market and provides statistics & information on market size, structure, and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global SGLT2 Inhibitors Market.

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]

Website: www.techsciresearch.com